Jaime Sepulveda
Urogynecology and Reconstructive Pelvic Surgery · South Miami, FLNPI 1366519167
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Lightscalpel Inc at 27.5% of the total. Reporting peaked in 2021 at $1,215 and has fallen 85.4% since, to $177 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in FL, where the typical reported total is $5,437.
Across 71 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lightscalpel Inc$880
- Astellas Pharma US Inc$427
- Coloplast$291
- AbbVie$276
- KARL Storz Endoscopy-america$210
- Mayne Pharma Commercial LLC$175
- plus $937 from 16 others
What the payments were for
- Speaking & faculty fees$88028%
- Food & beverage$1,71154%
- Education$39612%
- Gifts$2107%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lightscalpel Inc | 1 | $880 |
| Astellas Pharma US Inc | 10 | $427 |
| Coloplast | 6 | $291 |
| AbbVie(2 entities) | 13 | $276 |
| KARL Storz Endoscopy-america | 1 | $210 |
| Mayne Pharma Commercial LLC | 6 | $175 |
| Medtronic(2 entities) | 3 | $164 |
| Pfizer | 7 | $155 |
| Boston Scientific | 3 | $142 |
| Hologic Sales And Service, LLC | 3 | $91 |
| Therapeuticsmd, Inc. | 3 | $57 |
| Caldera Medical, Inc | 1 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Ascend Therapeutics US, LLC | 2 | $38 |
| Urovant Sciences Inc | 2 | $37 |
| Exeltis, USA Inc. | 2 | $32 |
| Meditrina | 1 | $25 |
| Lupin Inc. | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Provepharm Inc. | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,197 in reported general payments places this provider in the 30th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 16 | $944 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $315 |
| Clobetasol Propionate | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in South Miami
- Nathan KowOrlando$116K
- Amir ShariatiCoconut Creek$106K
- Charbel SalamonOrlando$100K
- Allison WymanTampa$69K
- Nicole SzellLargo$54K
- Jose Lazaro WeissOviedo$28K
- Paul PettitJacksonville$27K
- Arash RahiCoconut Creek$23K
- Moises VirellesWellington$21K
- Marja SprockRockledge$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.